Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Mini Review
  • Published:

Mini-Review

Nonablative hematopoietic cell transplantation for the treatment of metastatic renal cell carcinoma

Bone Marrow Transplantation volume 30, pages 805–812 (2002)Cite this article

Abstract

Nonablative hematopoietic cell transplantation (HCT) is becoming a preferred treatment for those recipients in whom the potential toxicity risk of standard ablative allogeneic therapy may be unacceptable. Graft-versus-malignancy effects may be generated against epithelial malignancies which are similar to the graft-versus-leukemia activity that is well documented in human hematological malignancies. Renal cell carcinoma has been shown to be responsive to immunotherapy with recombinant human cytokines and may be an ideal model for exploring this novel therapy. Clinical investigations have demonstrated regression of metastatic renal cell carcinoma occurs in some patients following nonablative allogeneic HCT. However, graft-versus-host disease remains a significant toxicity of nonablative transplantation, and further investigations are warranted to further evaluate this promising approach and to improve its safety.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Motzer RJ, Bander NH, Nanus DM . Renal-cell carcinoma New Engl J Med 1996 335: 865 875

    CAS  PubMed  Google Scholar 

  2. Linehan WM, Zbar B, Bates SE et al. Cancer of the kidney and ureter In: VT DeVita Jr, S Hellman, SA Rosenburg (eds) Cancer: Principles and Practice of Oncology, 6th edn Lippincott Williams and Wilkins: Philadelphia, PA 2001 pp 1362 1398

    Google Scholar 

  3. Montie JE, Stewart BH, Straffon RA et al. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma J Urol 1977 117: 272 275

    CAS  PubMed  Google Scholar 

  4. Gleave ME, Elhilali M, Fradet Y et al. Interferon gamm-Ib compared with placebo in metastatic renal cell carcinoma New Engl J Med 1998 338: 1265 1271

    CAS  PubMed  Google Scholar 

  5. Motzer RJ, Mazumdar M, Bacik J et al. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma J Clin Oncol 2000 18: 1928 1935

    CAS  PubMed  Google Scholar 

  6. Yagoda A, Petrylak D, Thompson S . Cytotoxic chemotherapy for advanced renal cell carcinoma Urol Clin N Am 1993 20: 303 321

    CAS  Google Scholar 

  7. Logan TF, Trump DL . The role of cytotoxic chemotherapy in the management of renal cancer. In: MS Ernstoff, JA Heaney, RE Peschel (eds) Urologic Cancer Blackwell Science: Cambridge 1997 444 463

    Google Scholar 

  8. Pastore RD, Pfeffer LM, Nanus DM . Renal cell carcinoma and interferon at the millennium Cancer Invest, 2001 19: 281 291

    CAS  Google Scholar 

  9. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer New Engl J Med 2001 345: 1655 1659

    CAS  PubMed  Google Scholar 

  10. Motzer RJ, Schwatrz L, Law TM et al. Interferon alpha 2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro J Clin Oncol 1995 13: 1950 1957

    CAS  PubMed  Google Scholar 

  11. Motzer RJ, Murphy BA, Bacik J et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma J Clin Oncol 2000 18: 2972 2980

    CAS  PubMed  Google Scholar 

  12. Atzpodien J, Kirchner H, Hanninen EL et al. Interleukin-2 in combination with interferon- and 5-fluorouracil for metastatic renal cell cancer Eur J Cancer 1993 29A: S6 S8

    PubMed  Google Scholar 

  13. Yang JC-Y . Interleukin-2: clinical applications. Renal cell carcinoma In: Rosenburg SA (ed.) Principles and Practice of the Biologic Therapy of Cancer, third edn Lippincott, Williams and Wilkins: Philadelphia 2000 pp. 73 82

    Google Scholar 

  14. Schwartzentruber DJ . Biologic therapy with Interleukin-2: clinical applications In: VT DeVita Jr, S Hellman, SA Rosenberg (eds) Biologic Therapy of Cancer, second edn JB Lippincott, Philadelphia 1995 pp. 235 249

    Google Scholar 

  15. Dutcher JP, Logan T, Gordon M et al. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study Clin Cancer Res 2000 6: 3442 3450

    CAS  PubMed  Google Scholar 

  16. Rosenberg SA, Yang JC, Topalian SL et al. The treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2 JAMA 1994 271: 907 913

    CAS  PubMed  Google Scholar 

  17. Fyfe G, Fisher RI, Rosenberg SA et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy J Clin Oncol 1995 13: 688 696

    CAS  PubMed  Google Scholar 

  18. Fisher RI, Rosenberg SA, Fyfe G . Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma Cancer J Sci Am 2000 6(Suppl. 1): S55 S57

    Google Scholar 

  19. Sleijfer DTH, Janssen RAJ, Butler J . Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis J Clin Oncol 1992 10: 1119 1123

    CAS  PubMed  Google Scholar 

  20. Yang JC, Topalian SL, Parkinson D et al. A randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report J Clin Oncol 1994 12: 1572 1576

    CAS  PubMed  Google Scholar 

  21. McDermott D, Flaherty L, Clark J et al. A randomized phase III trial of high-dose Interleukin-2 (HD IL-2) versus subcutaneous (SC) IL-2/Interferon (IFN) in patients with metastatic renal cell carcinoma (RCC) Proc ASCO 2001 20: 172a

    Google Scholar 

  22. Finke JH, Rayman P, Hart L et al. Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation J Immunother Emphasis Tumor Immunol 1994 15: 91 104

    CAS  PubMed  Google Scholar 

  23. Alexander JP, Kudoh S, Melsop KA et al. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors Cancer Res 1993 53: 1380 1387

    CAS  PubMed  Google Scholar 

  24. Gaugler B, Brouwenstijn N, Vantomme V et al. A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma Immunogenetics 1996 44: 323 330

    CAS  PubMed  Google Scholar 

  25. Brouwenstijn N, Gaugler B, Kruse KM et al. Renal cell carcinoma-specific lysis by cytotoxic T-lymphocyte clones isolated from peripheral blood lymphocytes and tumor-infiltrating lymphocytes Int J Cancer 1996 68: 177 182

    CAS  PubMed  Google Scholar 

  26. Bernhard H, Maurer MJ, Jager E et al. Recognition of human renal cell carcinoma and melanoma by HLA-A2-restricted cytotoxic T lymphocytes is mediated by shared peptide epitopes and up-regulated by interferon-gamma Scand J Immunol 1996 44: 285 292

    CAS  PubMed  Google Scholar 

  27. Caignard A, Guillard M, Gaudin C et al. In situ demonstration of renal cell carcinoma-specific T-cell clones Int J Cancer 1996 66: 564 570

    CAS  PubMed  Google Scholar 

  28. Bain C, Merrouche Y, Puisieux I et al. B7.1 gene transduction of human renal cell carcinoma cell lines restores the proliferative response and cytotoxic function of allogeneic T cells Int J Cancer 1996 67: 769 776

    CAS  PubMed  Google Scholar 

  29. Wang YC, Lihue Z, McHugh R et al. Induction of autologous tumor-specific cytotoxic T-lymphocyte activity against a human renal carcinoma cell line by B7-1 (CD80) costimulation J Immunother 1996 19: 1 8

    Google Scholar 

  30. Schendel DJ, Oberneder R, Falk CS et al. Cellular and molecular analyses of major histocompatibility complex (MHC) restricted and non-MHC-restricted effector cells recognizing renal cell carcinomas: problems and perspectives for immunotherapy J Mol Med 1997 75: 400 413

    CAS  PubMed  Google Scholar 

  31. Figlin RA, Pierce WC, Kaboo R et al. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8+ selected tumor-infiltrating lymphocytes from primary tumors J Urol 1997 158: 740 745

    CAS  PubMed  Google Scholar 

  32. Topalian SL, Solomon D, Avis FP et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study J Clin Oncol 1988 6: 839 853

    CAS  PubMed  Google Scholar 

  33. Kradin RL, Kurnick JT, Lazurus DS et al. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer Lancet 1989 1: 577 580

    CAS  PubMed  Google Scholar 

  34. Figlin RA, Thompson JA, Bukowski RM et al. Multicenter, randomized, phase III trial of CD8 (+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma J Clin Oncol 1999 17: 2521 2529

    CAS  PubMed  Google Scholar 

  35. Chang AE, Yoshizawa H, Sakai K et al. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro Cancer Res 1993 53: 1043 1050

    CAS  PubMed  Google Scholar 

  36. Chang AE, Aruga A, Cameron M et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2 J Clin Oncol 1997 15: 796 807

    CAS  PubMed  Google Scholar 

  37. Logan T, Kirkwood J, Wolmark N et al. Pilot study of in vitro sensitized (IVS) T cells in adoptive transfer therapy of cancer Proc ASCO 1990 9: Abstr. 726 188

    Google Scholar 

  38. Weidman E, Logan T, Yasumura S et al. Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes Cancer Res 1993 53: 4745 4749

    Google Scholar 

  39. Logan T, Banner B, Ernstoff M et al. Inflammatory cell infiltrate in a responding metastatic nodule after adoptive transfer of in vitro sensitized T cells and systemic interleukin-2 Clin Exp Immunol 1998 114: 347 354

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Lotze MT . Getting to the source: dendritic cells as therapeutic reagents for the treatment of patients with cancer Ann Surg 1997 226: 1 5

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Weber J, Schulz W . Clinical trials of dendritic cells for cancer Prin Prac Bio Ther Cancer Updates 2000 1: 1 12

    Google Scholar 

  42. Zitvogel L, Mayardomo JI, Tjandrawan T et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell-1-associated cytokines J Exp Med 1996 183: 87 97

    CAS  PubMed  Google Scholar 

  43. Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients with B-cell lymphomas using autologous antigen-pulsed dendritic cells Nat Med 1996 2: 52 58

    CAS  PubMed  Google Scholar 

  44. Reichardt VL, Okada CY, Liso A et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study Blood 1999 93: 2411 2419

    CAS  PubMed  Google Scholar 

  45. Murphy GP, Tjoa BA, Simmons SJ et al. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostrate cancer vaccine trial involving patients with hormone-refractory metastatic disease Prostate 1999 38: 73 78

    CAS  PubMed  Google Scholar 

  46. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells Nat Med 1998 4: 328 332

    CAS  PubMed  Google Scholar 

  47. Kugler A, Stuhler G, Walden P et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids Nat Med 2000 6: 332 336

    CAS  PubMed  Google Scholar 

  48. Storb R, Prentice RL, Hansen JA, Thomas ED . Association between HLA-B antigens and acute graft-versus-host disease Lancet 1983 2: 816 819

    CAS  PubMed  Google Scholar 

  49. Kersey JH, Meuwissen HJ, Yunis EJ, Good RA . Graft-versus-host reactions following transplantation of allogeneic hematopoietic cells Hum Pathol 1971 2: 389 402

    CAS  PubMed  Google Scholar 

  50. Bortin MM, Rimm AA, Saltzstein EC . Graft-versus-leukemia: quantification of adoptive immunotherapy in murine leukemia Science 1973 179: 811 813

    CAS  PubMed  Google Scholar 

  51. Odom L, August C, Githen J . Remission of relapsed leukemia during graft-versus-host reaction Lancet 1978 2: 537 540

    CAS  PubMed  Google Scholar 

  52. Weiden PL, Flourney N, Thomas ED et al. Anti-leukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow graft New Engl J Med 1979 300: 1068 1073

    CAS  PubMed  Google Scholar 

  53. Weisdorf DJ, Nesbit ME, Ramsey NK et al. Allogeneic bone marrow transplantation for acute lymphoblastic leukemia in remission: prolonged survival associated with acute graft-versus-host disease J Clin Oncol 1987 5: 1348 1355

    CAS  PubMed  Google Scholar 

  54. Higano CS, Brixey M, Bryant EM et al. Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect Transplantation 1990 50: 175 177

    CAS  PubMed  Google Scholar 

  55. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation Blood 1990 75: 555 562

    CAS  PubMed  Google Scholar 

  56. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia Blood 1995 86: 2041 2050

    CAS  PubMed  Google Scholar 

  57. Rondon G, Giralt S, Huh Y . Graft-versus-effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia Bone Marrow Transplant 1996 18: 669 672

    CAS  PubMed  Google Scholar 

  58. van Besien K, de Lima M, Giralt S et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect Bone Marrow Transplant 1997 19: 977 982

    CAS  PubMed  Google Scholar 

  59. Sykes M, Eisenthal A, Sachs DH . Mechanism of protection from graft-vs-host disease in murine mixed allogeneic chimeras J Immunol 1988 140: 2903 2911

    CAS  PubMed  Google Scholar 

  60. Sykes M, Sheard MA, Sachs DH . Graft-versus-host-related immunosuppression is induced in mixed chimeras by allo-responses against either host or donor lymphohematopoietic cells J Exp Med 1988 168: 2391 2396

    CAS  PubMed  Google Scholar 

  61. Sykes M, Bukhari Z, Sachs DH . Graft versus leukemia effect using mixed allogeneic bone marrow transplantation Bone Marrow Transplant 1989 4: 465 474

    CAS  PubMed  Google Scholar 

  62. Pelot MR, Person DA, Swenson K et al. Lymphopoietic graft-versus-host reactions can be induced without graft-versus-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen Biol Blood Marrow Transplant 1999 5: 133 143

    CAS  PubMed  Google Scholar 

  63. Storb R, Yu C, Wagner JL et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation Blood 1995 89: 3048 3054

    Google Scholar 

  64. Huss R, Deeg HJ, Gooley T et al. Effect of mixed chimerism on graft-versus-host disease, disease recurrence, and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia Bone Marrow Transplant 1996 18: 767 776

    CAS  PubMed  Google Scholar 

  65. Walters MC, Patience M, Leisenring W et al. Bone marrow transplantation for sickle cell disease New Engl J Med 1996 335: 369 376

    CAS  PubMed  Google Scholar 

  66. Andreani M, Manna M, Lucarelli G et al. Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia Blood 1996 87: 3494 3499

    CAS  PubMed  Google Scholar 

  67. Kapelushmik J, Or R, Filon D et al. Analysis of beta-globin mutations shows stable mixed chimerism in patients with thalassemia after bone marrow transplantation Blood 1995 86: 3241 3246

    Google Scholar 

  68. Weinberg RS, Vlachos A, Najfeld V et al. Disparate lympho-erythroid donor to recipient chimerism in a beta-thalassaemia bone marrow transplant recipient with red cell indices indicative of apparent full engraftment Br J Haematol 1997 99: 61 63

    CAS  PubMed  Google Scholar 

  69. Buckley RH, Schiff SE, Schiff RI et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency New Engl J Med 1999 340: 508 516

    CAS  PubMed  Google Scholar 

  70. Petz LD, Ulm P, Wallace RB et al. Mixed hematopoietic chimerism following bone marrow transplantation for hematologic malignancies Blood 1987 70: 1331 1337

    CAS  PubMed  Google Scholar 

  71. Lokhorst H, Schattenberg A, Cornelissen JJ et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation Blood 1997 90: 4206 4211

    CAS  PubMed  Google Scholar 

  72. Porter DL, Roth MS, McGarigle C . Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia New Engl J Med 1994 330: 100 104

    CAS  PubMed  Google Scholar 

  73. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation Blood 1996 87: 2195 2220

    CAS  PubMed  Google Scholar 

  74. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy Blood 1997 89: 4531 4536

    CAS  PubMed  Google Scholar 

  75. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 1998 91: 756 763

    CAS  PubMed  Google Scholar 

  76. Khouri IF, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies J Clin Oncol 1998 16: 2817 2824

    CAS  PubMed  Google Scholar 

  77. Storb R . Nonmyeloablative preparative regimens: experimental data and clinical practice In: Perry MC (ed.) American Society of Clinical Oncology Educational Book American Society of Clinical Oncology: Alexandria, VA 1999 pp. 241 246

    Google Scholar 

  78. Spitzer TR, Delmonico F, Tolkoff-Rubin N et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism Transplantation 1999 68: 480 484

    CAS  PubMed  Google Scholar 

  79. Childs R, Bahceci E, Clave E et al. Non-myeloablative allogeneic peripheral blood stem cell transplants (PBSCT) for malignant diseases reduces transplant-related mortality (TRM) Blood 1998 92: (Suppl. 1) 137a

    Google Scholar 

  80. Childs R, Clave E, Contentin N et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precede alloimmune responses Blood 1999 94: 3234 3241

    CAS  PubMed  Google Scholar 

  81. Champlin R, Khouri I, Anderlini P et al. Nonmyeloablative preparative regimens for allogeneic hematopoietic cell transplantation Bone Marrow Transplant 2001 27 (Suppl. 2): S13 S22

    Google Scholar 

  82. Giralt S, Slavin SE (eds). Non-myeloablative Stem Cell Transplantation (NST) Darwin Scientific Publishing: Abingdon 2000

    Google Scholar 

  83. Champlin R, Khouri I, Kornblau S et al. Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy Curr Opin Oncol 1999 11: 87 95

    CAS  PubMed  Google Scholar 

  84. Feinstein L, Storb R . Nonmyeloablative hematopoietic cell transplantation Curr Opin Oncol 2001 13: 95 100

    CAS  PubMed  Google Scholar 

  85. Storb R . Nonmyeloalbative preparative regimens: how relevant for acute myelogenous leukemia Leukemia 2001 15: 662 663

    CAS  PubMed  Google Scholar 

  86. Amado RG, Schiller GJ . Nonmyeloablative approaches to the treatment of sickle hemaglobinapathies Semin Oncol 2000 27: (Suppl. 2) 82 89

    CAS  PubMed  Google Scholar 

  87. Graber C, de Almeider KN, Childs R et al. CMV reactivation in nonmyeloablative HSCT Bone Marrow Transplant 2001 27: 775

    CAS  PubMed  Google Scholar 

  88. Spitzer TR . Nonmyeloablative allogeneic stem cell transplants strategies and mixed chimerism Oncologist 2000 5: 215 223

    CAS  PubMed  Google Scholar 

  89. Slavin S . New strategies for bone marrow transplantation Curr Opin Immunol 2000 12: 542 551

    CAS  PubMed  Google Scholar 

  90. Childs RW . Nonmyeloablative allogeneic peripheral blood stem-cell transplantation as immunotherapy for malignant diseases Cancer J Sci Am 2000 6: 179 187

    CAS  Google Scholar 

  91. Jursic JG, Cathcart K, Pinella-Ibarz J et al. Advances in immunotherapy of hematological malignancies: cellular and humoral approaches Curr Opin Hematol 2000 7: 247 254

    Google Scholar 

  92. Margolis J, Borrello I, Flinn IW . New approaches to treating malignancies with stem cell transplantation Semin Oncol 2000 27: 524 530

    CAS  PubMed  Google Scholar 

  93. Barrett AJ . Conditioning regimens for allogeneic stem cell transplants Curr Opin Hematol 2000 7: 339 342

    CAS  PubMed  Google Scholar 

  94. Childs R, Clave E, Tisdale J et al. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral blood progeniton cell transplant: evidence for a graft-versus-tumor effect J Clin Oncol 1999 17: 2044 2049

    CAS  PubMed  Google Scholar 

  95. Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral blood stem cell transplantation New Engl J Med 2000 343: 750 758

    CAS  PubMed  Google Scholar 

  96. Pedrazzoli P, Da Prada GA, Giorgiani G et al. Allogeneic blood stem cell transplantation after a reduced-intensity preparative regimen Cancer 2002 84: 2409 2415

    Google Scholar 

  97. Rini BI, Zimmerman T, Stadler WM et al. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment and clinical results J Clin Oncol 2002 20: 2017 2024

    PubMed  Google Scholar 

  98. Bregni M, Dodero A, Peccatori J et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer Blood 2002 99: 4234 4236

    CAS  PubMed  Google Scholar 

  99. Nimer SD, Giorgi J, Gajewski JL et al. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized controlled trial Transplantation 1994 57: 82 87

    CAS  PubMed  Google Scholar 

  100. Sandmaier BM, Masgood N, Thompson JA, Storb R . Fludarabine and total body radiation (TBI) followed by allogeneic hematopoietic stem cell transplant (HSCT) as immunotherapy for metastatic renal cell carcinoma (MRCC) Proc ASCO 2002 420a (Abstr. 1677)

  101. Ueno NT, Cheng YC, Giralt SA et al. Complete donor chimerism by fludarabine/melphalan in mini-allogeneic transplantation for metastatic renal cell carcinoma (RCC) and breast cancer (BC) Proc ASCO 2002 415a (Abstr. 1659)

Download references

Acknowledgements

We thank Samuel Bukantz, MD, for his careful review and Elizabeth Oda for here excellent secretarial service.

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Department of Medicine, Hematological Malignancy Program/Immunology, Bone Marrow Transplant Program, Indiana University School of Medicine, Indianapolis, IN, USA

    RP Nelson Jr & R Abonour

  2. Division of Hematology/Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA

    TF Logan

Authors
  1. RP Nelson Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. TF Logan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Abonour
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nelson, R., Logan, T. & Abonour, R. Nonablative hematopoietic cell transplantation for the treatment of metastatic renal cell carcinoma. Bone Marrow Transplant 30, 805–812 (2002). https://doi.org/10.1038/sj.bmt.1703740

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703740

Keywords

Search

Advanced search

Quick links